NEW YORK--(BUSINESS WIRE)--
(NASDAQ:MDSO), the leading global provider of cloud-based technology and
data analytics for clinical research, today announced that it will
release its second quarter 2017 financial results before the open of the
market on Tuesday, July 18, 2017. Tarek Sherif, chief executive officer,
and Rouven Bergmann, chief financial officer, will also hold a
conference call at 8:00 a.m. ET for investors and analysts to discuss
the Company's results and business outlook.
To participate by telephone, domestic participants may dial
1-877-303-2528 and international participants may dial 1-847-829-0023.
Those interested in participating in the conference call should dial in
at least 10 minutes prior to the call to register.
Participants can also join the call via a simultaneous live audio
webcast, which will be made available on the "Investor" section of
Medidata's website, http://investor.mdsol.com.
A replay of the conference call can be accessed through August 1, 2017,
by dialing 1-800-585-8367 domestically or 1-404-537-3406
internationally, with the passcode 46890165. An archive of the call will
also be hosted on the "Investor" section of Medidata's website, http://investor.mdsol.com,
for a limited period of time.
is reinventing global drug and medical device development by creating
the industry's leading cloud-based solutions for clinical research.
Through our advanced applications and intelligent data analytics,
Medidata helps advance the scientific goals of life sciences customers
worldwide, including over 850 global pharmaceutical companies, biotech,
diagnostic and device firms, leading academic medical centers, and
contract research organizations.
The Medidata Clinical Cloud® brings a new level of quality
and efficiency to clinical trials that empower our customers to make
more informed decisions earlier and faster. Our unparalleled clinical
trial data assets provide deep insights that pave the way for future
growth. The Medidata Clinical Cloud is the primary technology solution
powering clinical trials for 18 of the world's top 25 global
pharmaceutical companies and is used by 18 of the top 25 medical device
developers—from study design and planning through execution, management
View source version on businesswire.com: http://www.businesswire.com/news/home/20170705006031/en/
News Provided by Acquire Media